New solutions to treat Rubinstein-Taybi

Nov 18, 2021 | Short news

Ksilink was happy to welcome the team of Prof. Valérie Mezger-Lallemand from Université Diderot to initiate a collaboration with the aim to establish a new patient-based disease model to identify novel treatment options for patients suffering from Rubinstein-Taybi.

Rubinstein-Taybi is a rare disease, characterized by growth delays, distinctive facial features and intellectual disability. Over 60% of individuals with Rubinstein-Taybi syndrome display also autistic-like characteristics.

The project “RubiNeuroStress” receives funding from the ANR and ANRT. In this framework the Ksilink team is also happy to welcome a new PhD student, Carole Chaput.

Bonjour Carole et bienvenue parmi nous !

Share This